	US 12,234,227 B2
	Pyrazole derivatives as H4 antagonist compounds
Giles Albert Brown, Cambridge (GB); Miles Stuart Congreve, Cambridge (GB); Barry John Teobald, Cambridge (GB); Charlotte Fieldhouse, Cambridge (GB); Nigel Alan Swain, Cambridge (GB); Mark Pickworth, Cambridge (GB); and Giovanni Bottegoni, Cambridge (GB)
Assigned to NXERA PHARMA UK LIMITED, Cambridge (GB)
Appl. No. 17/285,776
Filed by NXERA PHARMA UK LIMITED, Cambridge (GB)
PCT Filed Oct. 21, 2019, PCT No. PCT/GB2019/052997 § 371(c)(1), (2) Date Apr. 15, 2021, PCT Pub. No. WO2020/079457, PCT Pub. Date Apr. 23, 2020.
Claims priority of application No. 1817047 (GB), filed on Oct. 19, 2018.
Prior Publication US 2021/0300906 A1, Sep. 30, 2021
Int. Cl. C07D 403/14 (2006.01); C07D 401/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)

CPC C07D 403/14 (2013.01) [C07D 401/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)]

17 Claims

1. A compound of the formula (1):

or a salt thereof, wherein;

X is CH or N;

n is 2;

R¹is selected from H or C_1-3alkyl;

R²is H or methyl; and

A represents an optionally substituted pyrazole ring which is linked to the ring containing X by a carbon-carbon bond, wherein A is selected from the group consisting of: